Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) reported its fourth quarter and full-year 2025 financial results, delivering a top-line revenue beat but a wider-than-expected loss per share. The company's shares moved lower in after-hours trading following the announcement, suggesting investor focus may be on the company's ongoing losses and a strategic restructuring plan that includes significant workforce reduction.
Earnings and Revenue Versus Estimates
The rare disease biopharmaceutical company posted mixed results relative to Wall Street expectations for the final quarter of 2025.
- Revenue: Ultragenyx reported Q4 2025 revenue of $207 million, surpassing the analyst consensus estimate of approximately $200.9 million. This represents a 25% increase over the $165 million reported in the same quarter of 2024.
- Earnings Per Share (EPS): The company reported a net loss per share of $1.29, which was larger than the estimated loss of $1.11 per share.
For the full year 2025, total revenue reached $673 million, a 20% year-over-year increase, driven by growth across its portfolio. The full-year net loss was $575 million, or $5.83 per share.
Market Reaction and Strategic Restructuring
The negative after-market price action, with shares down over 5%, appears to reflect a complex reaction to the report. While revenue growth remains robust, the wider quarterly loss and the company's forward-looking statements likely weighed on sentiment. A central component of the earnings release was the announcement of a "strategic restructuring plan" designed to significantly reduce expenses and refocus resources.
The plan includes an immediate 10% reduction in workforce, impacting approximately 130 employees. Management stated the restructuring, combined with anticipated revenue growth, is intended to keep the company on a "path to profitability in 2027." The company provided specific expense guidance, projecting that combined R&D and SG&A expenses for 2026 will be flat to down low-single digits versus 2025, including roughly $50 million in restructuring charges. By 2027, R&D expenses are expected to decrease by approximately $280 million from 2025 levels.
Financial Outlook Versus Analyst Expectations
Ultragenyx provided revenue guidance for 2026 based on its current product portfolio, excluding potential contributions from new launches. The company expects total revenue between $730 million and $760 million, which would represent growth of 8% to 13% over 2025.
This outlook can be compared to existing analyst sales estimates for the full year 2026, which stand at approximately $802.7 million. The company's guidance range, while showing growth, sits notably below this consensus figure, which may have contributed to the negative market reaction. The guidance implies that analysts' models may have been more optimistic about the near-term revenue trajectory of the existing commercial portfolio.
Key Highlights from the Earnings Report
Beyond the financial figures, the earnings release emphasized several critical corporate updates:
- Portfolio Growth: The company highlighted strong performance from its key products. Full-year revenue for Crysvita grew 17% to $481 million, while Evkeeza revenue surged 84% to $59 million.
- 2026 Catalysts: Management outlined several important near-term milestones, including:
- A PDUFA action date in Q3 2026 for DTX401, a gene therapy for Glycogen Storage Disease Type Ia.
- A resubmission of the BLA for UX111, a gene therapy for Sanfilippo syndrome type A, though the company noted it recently received an Incomplete Response Letter requesting additional documentation.
- Pivotal Phase 3 data expected in the second half of 2026 for GTX-102 in Angelman syndrome.
- Cash Position: The company ended the year with $737 million in cash, cash equivalents, and marketable securities.
For a detailed breakdown of past earnings and future estimates, you can review the data here.
Disclaimer: This article is for informational purposes only and does not constitute investment advice, financial analysis, or a recommendation to buy or sell any security. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions.